Chase Investment Counsel’s Regeneron Pharmaceuticals REGN Stock Holding History

Chase Investment Counsel’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-510	Closed	-$536K	–	146
2024 Q3	$536K	Sell	510 -97	-16%	-$108K	0.18%	85
2024 Q2	$637K	Hold	607	–	–	0.23%	87
2024 Q1	$584K	Buy	+607	New	+$577K	0.22%	92
2022 Q3	–	Sell	-798	Closed	-$471K	–	110
2022 Q2	$471K	Hold	798	–	–	0.25%	67
2022 Q1	$557K	Hold	798	–	–	0.24%	64
2021 Q4	$503K	Buy	+798	New	+$491K	0.2%	72
2021 Q1	–	Sell	-1,606	Closed	-$775K	–	116
2020 Q4	$775K	Sell	1,606 -3,730	-70%	-$2.01M	0.34%	59
2020 Q3	$2.99M	Sell	5,336 -489	-8%	-$296K	1.49%	25
2020 Q2	$3.63M	Sell	5,825 -1,331	-19%	-$755K	1.84%	15
2020 Q1	$3.49M	Buy	+7,156	New	+$2.95M	2.36%	18

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Chase Investment Counsel's REGN Position: Q4 2024 in Review

Chase Investment Counsel sold out of Regeneron Pharmaceuticals (REGN) in Q4 2024, closing a stake of 510 shares — an estimated $536K sold.

Chase Investment Counsel first reported a position in REGN in Q1 2020 and held it in 10 quarters. The position peaked at $3.63M in Q2 2020. 1,320 funds tracked by Wall St. Rank hold REGN as of Q4 2024.

Chase Investment Counsel reported no remaining Regeneron Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Chase Investment Counsel sold 510 Regeneron Pharmaceuticals shares in Q4 2024, an estimated $536K.
Chase Investment Counsel first reported a position in Regeneron Pharmaceuticals in Q1 2020 and held it in 10 quarters.
Chase Investment Counsel's Regeneron Pharmaceuticals position peaked at $3.63M in Q2 2020.
1,320 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2024.

Based on Chase Investment Counsel's 13F filing for Q4 2024, filed 5 Feb 2025.